Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer

NCT01949337 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT01949337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01949337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 3
Overall status
Unknown status
Start date
January 22, 2014
Completion date
August 31, 2024
Enrollment
1,311 (actual)
Sites
539

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the prostate, hormone-resistant prostate cancer, recurrent prostate cancer, stage iv prostate cancer